Higher FOXP3/CD8, FOXP3+PD-1/CD8, and CD32B/CD19 ratios were linked to more advanced disease features and shorter disease-free survival, suggesting a more immunosuppressive tumor microenvironment. This evidence concerns the gene CD19 and neoplasm.